The breast cancer liquid biopsy market is expanding as a non-invasive alternative to traditional biopsies. It allows early detection, monitoring, and treatment planning through blood-based biomarkers. Advances in next-generation sequencing and circulating tumor DNA (ctDNA) analysis are driving adoption, especially in personalized oncology and real-time assessment of therapeutic response.
Read More: https://www.imarcgroup.com...